These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Twice-a-day Crixivan study discontinued. Newsline People AIDS Coalit N Y; 1998; ():31. PubMed ID: 11367502 [TBL] [Abstract][Full Text] [Related]
4. Crixivan (Indinavir): three doses daily, not two, in most regimens. James JS AIDS Treat News; 1998 Oct; (No 304):4-5. PubMed ID: 11365863 [TBL] [Abstract][Full Text] [Related]
5. Twice-daily dosing Crixivan study discontinued. WORLD; 1998 Oct; (No 90):7. PubMed ID: 11365922 [TBL] [Abstract][Full Text] [Related]
7. Crixivan warning: keep to three times a day. Gilden D GMHC Treat Issues; 1998 Sep; 12(9):2. PubMed ID: 11365805 [TBL] [Abstract][Full Text] [Related]
8. No more twice-a-day Crixivan. Vazquez E Posit Aware; 1998; 9(6):17. PubMed ID: 11366469 [TBL] [Abstract][Full Text] [Related]
9. Health-related quality of life in HIV patients switching to twice-daily indinavir/ritonavir regimen or continuing with three-times-daily indinavir-based therapy. Badía X; Podzamczer D; Moral I; Roset M; Arnaiz JA; Loncà M; Casiró A; Rosón B; Gatell JM; Antivir Ther; 2004 Dec; 9(6):979-85. PubMed ID: 15651756 [TBL] [Abstract][Full Text] [Related]
10. Update from the 5th Conference on Retroviruses and Opportunistic Infections. Vazquez E Posit Aware; 1998; 9(3):21-3. PubMed ID: 11365483 [TBL] [Abstract][Full Text] [Related]
11. The choice of HIV protease inhibitor: indinavir is currently the best option. Prescrire Int; 1999 Apr; 8(40):55-60. PubMed ID: 10848067 [TBL] [Abstract][Full Text] [Related]
12. Merck pushes the envelope with once-daily indinavir. TreatmentUpdate; 2001; 12(12):8. PubMed ID: 11570096 [No Abstract] [Full Text] [Related]